O-GlcNAcylation: The sweet side of the cancer

Frontiers in Oncology

Volumn 4 JUN, Issue , 2014, Pages

  Queiroz, Rafaela Muniz de ^a   Carvalho, Érika ^a   Dias, Wagner Barbosa ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cancer; Metabolism; Metastasis; O GlcNAc; O GlcNAcylation; Review; Tumor biology; Tumorigenesis

Indexed keywords

GLUTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; N ACETYLGLUCOSAMINE; O LINKED BETA N ACETYLGLUCOSAMINE; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CITRIC ACID CYCLE; COLON CANCER; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GENE SILENCING; GLYCOLYSIS; HUMAN; IMMUNOBLOTTING; IMMUNOCHEMISTRY; INTRACELLULAR SIGNALING; LIVER CANCER; LONG TERM SURVIVAL; LUNG CANCER; METASTASIS; MRNA EXPRESSION ASSAY; NEOPLASM; ONCOGENE C MYC; ONCOGENE RAS; PANCREAS CANCER; PROSTATE CANCER; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; THYROID CANCER;

EID: 84904620640     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00132     Document Type: Review

References (77)

1. Torres CR, Hart GW. Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem (1984) 259(5):3308-17.
2. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature (2007) 446(7139):1017-22. doi:10.1038/nature05815
3. O'Donnell N, Zachara NE, Hart GW, Marth JD. Ogt-dependent X-chromosome-linked protein glycosylation is a requisite modification in somatic cell function and embryo viability. Mol Cell Biol (2004) 24(4):1680-90. doi:10.1128/MCB.24.4.1680-1690.2004
4. Whelan SA, Dias WB, Thiruneelakantapillai L, Lane MD, Hart GW. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem (2010) 285(8):5204-11. doi:10.1074/jbc.M109.077818
5. Slawson C, Lakshmanan T, Knapp S, Hart GW. A mitotic GlcNAcylation/phosphorylation signaling complex alters the posttranslational state of the cytoskeletal protein vimentin. Mol Biol Cell (2008) 19(10):4130-40. doi:10.1091/mbc.E07-11-1146
6. Dias WB, Cheung WD, Wang Z, Hart GW. Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc modification. J Biol Chem (2009) 284(32):21327-37. doi:10.1074/jbc.M109.007310
7. Dias WB, Cheung WD, Hart GW. O-GlcNAcylation of kinases. Biochem Biophys Res Commun (2012) 422(2):224-8. doi:10.1016/j.bbrc.2012.04.124
8. Ostrowski A, von Aalten DM. Chemical tools to probe cellular O-GlcNAc signalling. Biochem J (2013) 456(1):1-12. doi:10.1042/BJ20131081
9. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab (2006) 290(1):E1-8. doi:10.1152/ajpendo.00329.2005
10. Kreppel LK, Hart GW. Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem (1999) 274(45):32015-22. doi:10.1074/jbc.274.45.32015
11. Dias WB, Hart GW. O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst (2007) 3(11):766-72. doi:10.1039/b704905f
12. Slawson C, Hart GW. O-GlcNAc signalling: implications for cancer cell biology. Nat Rev Cancer (2011) 11(9):678-84. doi:10.1038/nrc3114
13. Warburg O. On respiratory impairment in cancer cells. Science (1956) 124(3215):269-70.
14. Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD, et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) (2011) 66(6):965-72. doi:10.1590/S1807-59322011000600008
15. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 2(9):683-93. doi:10.1038/nrc882
16. Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, et al. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res (2013) 73(16):5277-87. doi:10.1158/0008-5472.CAN-13-0549
17. Alisson-Silva F, Freire-de-Lima L, Donadio JL, Lucena MC, Penha L, Sá-Diniz JN, et al. Increase of O-glycosylated oncofetal fibronectin in high glucose-induced epithelial-mesenchymal transition of cultured human epithelial cells. PLoS One (2013) 8(4):e60471. doi:10.1371/journal.pone.0060471
18. Dennis JW, Lau KS, Demetriou M, Nabi IR. Adaptive regulation at the cell surface by N-glycosylation. Traffic (2009) 10(11):1569-78. doi:10.1111/j.16000854.2009.00981.x
19. Fardini Y, Dehennaut V, Lefebvre T, Issad T. O-GlcNAcylation: a new cancer hallmark? Front Endocrinol (Lausanne) (2013) 4:99. doi:10.3389/fendo.2013.00099
20. Ma Z, Vosseller K. O-GlcNAc in cancer biology. Amino Acids (2013) 45(4):719-33. doi:10.1007/s00726-013-1543-8
21. Gu Y, Mi W, Ge Y, Liu H, Fan Q, Han C, et al. GlcNAcylation plays an essential role in breast cancer metastasis. Cancer Res (2010) 70(15):6344-51. doi:10.1158/0008-5472.CAN-09-1887
22. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S, et al. Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene (2010) 29(19):2831-42. doi:10.1038/onc.2010.41
23. Champattanachai V, Netsirisawan P, Chaiyawat P, Phueaouan T, Charoenwattanasatien R, Chokchaichamnankit D, et al. Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer. Proteomics (2013) 13:2088-99. doi:10.1002/pmic.201200126
24. Krzeslak A, Forma E, Bernaciak M, Romanowicz H, Brys M. Gene expression of O-GlcNAc cycling enzymes in human breast cancers. Clin Exp Med (2012) 12(1):61-5. doi:10.1007/s10238-011-0138-5
25. Slawson C, Pidala J, Potter R. Increased N-acetyl-ß-glucosaminidase activity in primary breast carcinomas corresponds to a decrease in N-acetylglucosamine containing proteins. Biochim Biophys Acta (2001) 1537(2):147-57. doi:10.1016/S0925-4439(01)00067-9
26. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked ß-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem (2012) 287:11070-81. doi:10.1074/jbc.M111.302547
27. Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O, Nakayama J. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis (2013) 17(1):18-22. doi:10.1038/pcan.2013.56
28. Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, et al. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta (2011) 1812(4):514-9. doi:10.1016/j.bbadis.2011.01.009
29. Phueaouan T, Chaiyawat P, Netsirisawan P, Chokchaichamnankit D, Punyarit P, Srisomsap C, et al. Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer. Oncol Rep (2013) 30(6):2929-36. doi:10.3892/or.2013.2794
30. Yehezkel G, Cohen L, Kliger A, Manor E, Khalaila I. O-linked ß-N-acetylglucosaminylation (O-GlcNAcylation) in primary and metastatic colorectal cancer clones and effect of N-acetyl-ß-D-glucosaminidase silencing on cell phenotype and transcriptome. J Biol Chem (2012) 287(34):28755-69. doi:10.1074/jbc.M112.345546
31. Rozanski W, Krzeslak A, Forma E, Brys M, Blewniewski M, Wozniak P, et al. Prediction of bladder cancer based on urinary content of MGEA5 and OGT mRNA level. Clin Lab (2012) 58(5-6):579-83.
32. Shi Y, Tomic J, Wen F, Shaha S, Bahlo A, Harrison R, et al. Aberrant O-GlcNAcylation characterizes chronic lymphocytic leukemia. Leukemia (2010) 24(9):1588-98. doi:10.1038/leu.2010.152
33. Krzeslak A, Wójcik-Krowiranda K, Forma E, Bienkiewicz A, Brys M. Expression of genes encoding for enzymes associated with O-GlcNAcylation in endometrial carcinomas: clinicopathologic correlations. Ginekol Pol (2012) 83(1):22-6.
34. Zhu Q, Zhou L, Yang Z, Lai M, Xie H, Wu L, et al. O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation. Med Oncol (2012) 29(2):985-93. doi:10.1007/s12032-011-9912-1
35. Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-?B activity in pancreatic cancer cells. J Biol Chem (2013) 288:15121-30. doi:10.1074/jbc.M113.470047
36. Krzeslak A, Józwiak P, Lipinska A. Down-regulation of ß-N-acetyl-D-glucosaminidase increases Akt1 activity in thyroid anaplastic cancer cells. Oncol Rep (2011) 26(3):743-9. doi:10.3892/or.2011.1333
37. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013
38. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev (2009) 23(5):537-48. doi:10.1101/gad.1756509
39. Clark PM, Dweck JF, Mason DE, Hart CR, Buck SB, Peters EC, et al. Direct in-gel fluorescence detection and cellular imaging of O-GlcNAc-modified proteins. J Am Chem Soc (2008) 130:11576-7. doi:10.1021/ja8030467
40. Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA III, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science (2012) 337(6097):975-80. doi:10.1126/science.1222278
41. Yuneva MO, Fan TW, Allen TD, Higashi RM, Ferraris DV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 15:157-70. doi:10.1016/j.cmet.2011.12.015
42. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 496:101-5. doi:10.1038/nature12040
43. Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet (2011) 7:e1002229. doi:10.1371/journal.pgen.1002229
44. Sutendra G, Michelakis ED. Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol (2013) 3:38. doi:10.3389/fonc.2013.00038
45. Love DC, Kochan J, Cathey RL, Shin SH, Hanover JA. Mitochondrial and nucleocytoplasmic targeting of O-linked GlcNAc transferase. J Cell Sci (2003) 116:647-54. doi:10.1242/jcs.00246
46. Shin SH, Love DC, Hanover JA. Elevated O-GlcNAc-dependent signaling through inducible mOGT expression selectively triggers apoptosis. Amino Acids (2011) 40:885-93. doi:10.1007/s00726-010-0719-8
47. Hu Y, Suarez J, Fricovsky E, Wang H, Scott BT, TRauger SA, et al. Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose. J Biol Chem (2009) 284:547-55. doi:10.1074/jbc.M808518200
48. Tan EP, Villar MT, E L, Lu J, Selfridge JE, Artigues A, et al. Altering O-linked ß-N-acetylglucosamine cycling disrupts mitochondrial function. J Biol Chem (2014) 289:14719-30. doi:10.1074/jbc.M113.525790
49. Inoue-Yamauchi A, Oda H. Depletion of mitochondrial fission factor DRP1 causes increased apoptosis in human colon cancer cells. Biochem Biophys Res Commun (2012) 421:81-5. doi:10.1016/j.bbrc.2012.03.118
50. Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, et al. Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene (2012) 32(40):4814-24. doi:10.1038/onc.2012.494
51. Qian W, Wang J, Van Houten B. The role of dynamin-related protein 1 in cancer growth: a promising therapeutic target? Expert Opin Ther Targets (2013) 17:997-1001. doi:10.1517/14728222.2013.823160
52. Gawlowski T, Suarez J, Scott B, Torres-Gonzalez M, Wang H, Schwappacher R, et al. Modulation of dynamin-related protein 1 (DRP1) function by increased O-linked-ß-N-acetylglucosamine modification (O-GlcNAc) in cardiac myocytes. J Biol Chem (2012) 287:30024-34. doi:10.1074/jbc.M112.390682
53. Onodera Y, Nam JM, Bissell MJ. Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Invest (2014) 124(1):367-84. doi:10.1172/JCI63146
54. Kanwal S, Fardini Y, Pagesy P, N'tumba-Byn T, Pierre-Eugène C, Masson E, et al. O-GlcNAcylation-inducing treatments inhibit estrogen receptor a expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells. PLoS One (2013) 8(7):e69150. doi:10.1371/journal.pone.0069150
55. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett (2006) 580(12):2903-9. doi:10.1016/j.febslet.2006.02.020
56. Huang X, Pan Q, Sun D, Chen W, Shen A, Huang M, et al. O-GlcNAcylation of cofilin promotes breast cancer cell invasion. J Biol Chem (2013) 288(51):36418-25. doi:10.1074/jbc.M113.495713
57. Khan Z, Bisen PS. Oncoapoptotic signaling and deregulated target genes in cancers: special reference to oral cancer. Biochim Biophys Acta (2013) 1836(1):123-45. doi:10.1016/j.bbcan.2013.04.002
58. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol (2006) 16(4):318-30. doi:10.1016/j.semcancer.2006.07.015
59. Chou TY, Hart GW, Dang CV. c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas. J Biol Chem (1995) 270(32):18961-5. doi:10.1074/jbc.270.32.18961
60. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev (2000) 14:2501-14. doi:10.1101/gad.836800
61. Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS, et al. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol (2006) 8(10):1074-83 Erratum in: Nat Cell Biol (2007) 9(12):1442. doi:10.1038/ncb1470
62. Soesanto YA, Luo B, Jones D, Taylor R, Gabrielsen JS, Parker G, et al. Regulation of Akt signaling by O-GlcNAc in euglycemia. Am J Physiol Endocrinol Metab (2008) 295(4):E974-80. doi:10.1152/ajpendo.90366.2008
63. Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, et al. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol (2004) 22(24):4901-6. doi:10.1200/jco.2004.05.071
64. Hsu CH, Yang SA, Wang JY, Yu HS, Lin SR. Mutational spectrum of p53 gene in arsenic-related skin cancers from the blackfoot disease endemic area of Taiwan. Br J Cancer (1999) 80:1080-6. doi:10.1038/sj.bjc.6690467
65. Fernández-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer (2011) 2(3):344-58. doi:10.1177/1947601911411084
66. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 20(10):1218-49. doi:10.1101/gad.1415606
67. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res (1989) 49(17):4682-9 Erratum in: Cancer Res (1990) 50(4):1352.
68. Ying H, Kimmelman AC, Lyssiotis CA, Chu S, Fletcher-Sananikone E, Locasale JW, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 149(3):656-70. doi:10.1016/j.cell.2012.01.058
69. Palorini R, Cammarata FP, Balestrieri C, Monestiroli A, Vasso M, Gelfi C, et al. Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response. Cell Death Dis (2013) 4:e732. doi:10.1038/cddis.2013.257
70. Kim I, He YY. Targeting the AMP-activated protein kinase for cancer prevention and therapy. Front Oncol (2013) 3:175. doi:10.3389/fonc.2013.00175
71. Cheung WD, Hart GW. AMP-activated protein kinase and p38 MAPK activate O-GlcNAcylation of neuronal proteins during glucose deprivation. J Biol Chem (2008) 283(19):13009-20. doi:10.1074/jbc.M801222200
72. Bullen JW, Balsbaugh JL, Chanda D, Shabanowitz J, Hunt DF, Neumann D, et al. Crosstalk between two essential nutrient-sensitive enzymes: O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK). J Biol Chem (2014) 289:10592-606. doi:10.1074/jbc.M113.523068
73. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 2(6):a000109. doi:10.1101/cshperspect.a000109
74. Liu W, Zhang X, Liu P, Shen X, Lan T, Li W, et al. Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. Eur J Pharmacol (2010) 638(1-3):150-5. doi:10.1016/j.ejphar.2010.04.033
75. Yang WH, Park SY, Nam HW, Kim Do H, Kang JG, Kang ES, et al. NFkappaB activation is associated with its O-GlcNAcylation state under hyperglycemic conditions. Proc Natl Acad Sci U S A (2008) 105(45):17345-50. doi:10.1073/pnas.0806198105
76. Allison DF, Wamsley JJ, Kumar M, Li D, Gray LG, Hart GW, et al. Modification of RelA by O-linked N-acetylglucosamine links glucose metabolism to NF-?B acetylation and transcription. Proc Natl Acad Sci U S A (2012) 109(42):16888-93. doi:10.1073/pnas.1208468109
77. Kawauchi K, Araki K, Tobiume K, Tanaka N. Loss of p53 enhances catalytic activity of IKKß through O-linked ß-N-acetyl glucosamine modification. Proc Natl Acad Sci U S A (2009) 106(9):3431-6. doi:10.1073/pnas.0813210106